Registered outcomes11

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 11 of 11

List	Outcome	Time frame	Description
Primary	Supplemental Oxygen Requirement	14 days maintained up to 42 days	To compare the proportion of patients no longer requiring supplemental oxygen for at least 24 hours by Day 14 between subjects taking opaganib and those on placebo.
Secondary	Percentage of Subjects With ≥ 2 Category Improvement on the World Health Organization (WHO) Ordinal Scale for Clinical Improvement by Day 14 Maintained to Day 42	14 days maintained up to 42 days	Compare ≥2 category improvement on the WHO Ordinal Scale for Clinical Improvement from 0(uninfected) to 8(death) for subjects taking opaganib and those on placebo, lower scores indicate improvement. Success was defined as subject who reached improvement of at least two points on the WHO Ordinal Scale by Day 14, maintained by the end of study visit, and failure otherwise.
Secondary	Number of Subjects With Improvement to a Score of 3 or Less on the WHO Ordinal Scale for Clinical Improvement With a Scale Ranging From 8 Down to 0	14 days maintained up to 42 days	Compare scores of subjects taking opaganib and those on placebo, lower scores indicate improvement to determine time to recovery as defined by improvement to a score of 3 or less on the WHO Ordinal Scale for Clinical Improvement with a scale ranging from 0 (uninfected) to 8 (death)
Secondary	Number of Participants With Low Oxygen Flow Via Nasal Cannula	14 days maintained up to 42 days	To compare the time to low oxygen flow via nasal cannula e.g. from high oxygen flow via nasal cannula or CPAP, if high oxygen flow is not an available option between subjects taking opaganib and those on placebo.
Secondary	Time to Discharge From Hospital Measured at 14 Days	14 days	Time to subject discharge from hospital
Secondary	Patients Requiring Intubation and Mechanical Ventilation by Day 42	42 days	To compare the proportion of patients requiring intubation and mechanical ventilation between subjects taking opaganib and those on placebo.
Secondary	Number of Patients With Two Consecutive Negative Swabs for SARS-CoV-2 at Day 14	14 days	To compare the number of patients with two consecutive negative swabs for SARS-CoV-2 by PCR at Day 14 between subjects taking opaganib and those on placebo.
Secondary	Patients With Negative Swabs for SARS-CoV-2 at Day 14	14 days	To compare the proportion of patients with two consecutive negative swabs for SARS-CoV-2 by PCR at Day 14 between subjects taking opaganib and those on placebo.
Secondary	Mortality Due to Any Cause	28 days	To compare mortality 28 days post-baseline between subjects taking opaganib and those taking placebo
Secondary	Mortality Due to Any Cause	42 days	To compare mortality 42 days post-baseline between subjects taking opaganib and those taking placebo
Other	Number of Participants With Treatment Emergent Adverse Events (TEAEs)	From first dose until 4 weeks follow-up after the end of treatment	To compare the number of participants with treatment emergent adverse events (TEAEs) in patients with severe COVID-19 pneumonia between participants taking opaganib and participants taking placebo

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04467840/registered

API reference For AI assistants